CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to create a predictive assay for breast cancer treatment based on the HOXC11 biomarker. It seeks to establish a partnership between industry and academia to develop a clinically validated tool for personalized medicine.
Classical pathologic parameters have been used to inform adjuvant clinical treatment choices for early breast cancer patients.
There remain a significant number of patients however, who despite a reportedly favourable prognostic profile, experience metastatic disease.
Elucidation of the mechanisms of tumour adaptability and the identification of predictive markers of early recurrence is the basis of personalized medicine.
Work from our group has established the developmental protein HOXC11 as…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, CRAIGAVON
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
